Clincosm LogoSign in Get a demo

Refractory Acute Lymphoblastic Leukemia

Showing 1 - 25 of 29
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia

Not yet recruiting
  • Recurrent Acute Leukemia of Ambiguous Lineage
  • +5 more
  • Biospecimen Collection
  • +12 more
  • (no location specified)
Mar 8, 2023

Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia Trial in

Suspended
  • Juvenile Myelomonocytic Leukemia
  • +27 more
  • CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 11, 2023

CAR, Refractory Acute Lymphoblastic Leukemia, Relapsed Adult ALL Trial in Suzhou (Treatment)

Recruiting
  • CAR
  • +2 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Dec 27, 2022

Lymphoid Leukemia, Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Tampa (CPX-351)

Active, not recruiting
Has Results
  • Lymphoid Leukemia
  • +3 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Dec 30, 2022

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein

Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +7 more
  • Blinatumomab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic

Active, not recruiting
  • Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 2, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +15 more
  • Anti-CD19/CD20/CD22 CAR T-Cells
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 4, 2022

Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid

Recruiting
  • Acute Lymphoblastic Leukemia in Remission
  • +11 more
  • Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 24, 2022

Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia Trial in Miami (Pevonedistat, Vincristine,

Completed
  • Refractory Acute Lymphoblastic Leukemia
  • Relapsed Acute Lymphoblastic Leukemia
  • Miami, Florida
    University of Miami
Oct 19, 2022

Hematopoietic and Lymphoid Cell Tumor, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Trial in Houston

Active, not recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 6, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia Trial in Houston

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 21, 2022

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia

Recruiting
  • Acute Lymphoblastic Leukemia
  • +11 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 29, 2022

Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia Trial in Memphis (drug, biological, radiation)

Not yet recruiting
  • Refractory Acute Lymphoblastic Leukemia
  • Relapsed Acute Lymphoblastic Leukemia
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Aug 23, 2022

Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia Trial in Beijing

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • Autologous humanized anti-CD22 chimeric antigen receptor T cells
  • Beijing, Beijing, China
    Beijing Boren Hospital
Aug 12, 2022

Relapsed Pediatric ALL, Relapsed Pediatric AML, Refractory Acute Myeloid Leukemia Trial in Kansas City (Daunorubicin)

Recruiting
  • Relapsed Pediatric ALL
  • +3 more
  • Kansas City, Missouri
    Children's Mercy Hospital
Jul 1, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2022

Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Trial in

Completed
Has Results
  • Recurrent Acute Leukemia of Ambiguous Lineage
  • +5 more
  • Chemosensitivity Assay
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jun 29, 2022

Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia Trial in China (pCAR-19B cells)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • pCAR-19B cells
  • Beijing, Beijing, China
  • +9 more
May 19, 2022

Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia Trial in Wuhan (pCAR-19B cells)

Completed
  • Acute Lymphoblastic Leukemia
  • +2 more
  • pCAR-19B cells
  • Wuhan, Hubei, China
    Tongji Hospital affiliated to Tongji Medical College of Huazhong
Mar 16, 2022

Chemo Resistant Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Philadelphia (CART22-65s cells,

Active, not recruiting
  • Chemotherapy Resistant Acute Lymphoblastic Leukemia
  • Refractory Acute Lymphoblastic Leukemia
  • CART22-65s cells
  • huCART19 Cells
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Feb 18, 2022

AML/MDS, CMML, Relapse Trial in China, Spain, United States (LP-108, LP-108 and azacitidine)

Recruiting
  • AML/MDS
  • +5 more
  • Ann Arbor, Michigan
  • +7 more
Feb 14, 2022

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With

Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +5 more
  • Blinatumomab
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 1, 2022

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells,

Terminated
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +10 more
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
Nov 17, 2021

Acute Lymphoblastic Leukemia, Pediatric, Relapsed Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in

Recruiting
  • Acute Lymphoblastic Leukemia, Pediatric
  • +2 more
  • Stanford, California
    Lucile Packard Children's Hospital Stanford
Sep 20, 2021

Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia Trial in Wuhan (pCAR-19B cells)

Recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • Refractory Acute Lymphoblastic Leukemia
  • pCAR-19B cells
  • Wuhan, Hubei, China
    Tongji Hospital affiliated to Tongji Medical College of Huazhong
May 12, 2021